Position in ENGN
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$294,100
-$2,103,612 QoQ
Shares Held
170,000
-51.7% QoQ
Ownership
0.254%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#31
of 60 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Privium Fund Management B.V. holds $162,489,015 across 32 Biotechnology names. ENGN ranks #32 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
319,924 | $25,366,773 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
234,222 | $19,091,435 | |
| 3 | QURE |
uniQure N.V.
|
328,322 | $15,122,511 | |
| 4 | RARE |
Ultragenyx Pharmaceutical Inc.
|
338,800 | $11,312,532 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
|
399,367 | $10,471,402 | |
| 6 | PRQR |
ProQR Therapeutics N.V.
|
5,520,024 | $10,267,244 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
39,944 | $9,777,092 | |
| 8 | URGN |
UroGen Pharma Ltd.
|
210,000 | $7,728,000 |
All Filings in ENGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $294,100 | 170,000 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $2,397,712 | 352,087 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $3,179,345 | 352,087 | Shares | Sole | 2026-02-03 | |
| No filing history on record for this holder in this stock. | ||||||